Home > Healthcare > Medical Devices > Infection Control > Hospital Acquired Infections (HAI) Diagnostics Market

Hospital Acquired Infections (HAI) Diagnostics Market Share

Report ID: GMI5912
Published Date: Jun 2023
Report Format: PDF

Download Free Sample

Hospital Acquired Infections (HAI) Diagnostics Market Share

Some of the major market players operating in the hospital acquired infections diagnostics market are:

Abbott Laboratories
Bayer
Becton Dickinson And Company
Biomérieux
Danaher Corporation
Ecolab

Major market players are adopting strategic formulations such as forward integration, new product development, geographical expansion, and research collaborations to garner maximum industry share and promote company growth.

Authors: Mariam Faizullabhoy

Frequently Asked Questions (FAQ) :

The hospital acquired infections (HAI) diagnostics market was valued at around USD 4.5 billion in 2022 and is estimated to reach over USD 10 billion by the end of 2032, owing to the technological advancements, increased awareness, and government initiatives to safeguard public health.

The immunoassays segment was valued at around USD 1.7 billion in 2023. The immunodiagnostic tests for HAIs can help identify specific pathogens responsible for the infection, monitor the patient's immune response, and determine appropriate treatment strategies.

U.S. dominated the North America hospital acquired infections (HAI) diagnostics market with a significant market share in 2022 and will reach around USD 4.2 billion by 2032, backed by the increasing prevalence of HAI, emphasis on infection control & prevention, and technological advancements.

Abbott Laboratories, Bayer, Becton Dickinson And Company, Biom